A nanoparticle carrying the p53 gene targets tumors including cancer stem cells, sensitizes glioblastoma to chemotherapy and improves survival

ACS Nano

Volumn 8, Issue 6, 2014, Pages 5494-5514

  Kim, Sang Soo ^a   Rait, Antonina ^a   Kim, Eric ^b   Pirollo, Kathleen F ^a   Nishida, Maki ^b   Farkas, Natalia ^c   Dagata, John A ^c   Chang, Esther H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b SynerGene Therapeutics Inc   (United States)

^c NATIONAL INSTITUTE OF STANDARDS AND TECHNOLOGY   (United States)

Author keywords

chemosensitization; crossing BBB; CSC apoptosis; glioblastoma multiforme; MGMT down modulation; p53 nanoparticle gene therapy; tumor CSC targeting

Indexed keywords

CELL DEATH; CHEMOTHERAPY; ENZYME INHIBITION; NANOPARTICLES; STEM CELLS; TUMORS;

ANTI-TUMOR EFFICACY; BLOOD-BRAIN BARRIER; CHEMO SENSITIZATIONS; GLIOBLASTOMA MULTIFORME; METHYLTRANSFERASES; MGMT DOWN-MODULATION; SYSTEMIC DELIVERIES; TUMOR-SPECIFIC TARGETING;

DISEASES;

ANTINEOPLASTIC AGENT; DACARBAZINE; NANOPARTICLE; PROTEIN P53; TEMOZOLOMIDE; TP53 PROTEIN, HUMAN;

ANALOGS AND DERIVATIVES; ANIMAL; APOPTOSIS; ATOMIC FORCE MICROSCOPY; BLOOD BRAIN BARRIER; BRAIN NEOPLASMS; CANCER STEM CELL; CANCER TRANSPLANTATION; CHEMISTRY; DRUG EFFECTS; DRUG RESISTANCE; GENE THERAPY; GENETICS; GLIOBLASTOMA; HUMAN; MOUSE; NANOMEDICINE; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; TUMOR RECURRENCE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOOD-BRAIN BARRIER; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG RESISTANCE, NEOPLASM; GENETIC THERAPY; GLIOBLASTOMA; HUMANS; MICE; MICROSCOPY, ATOMIC FORCE; NANOMEDICINE; NANOPARTICLES; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; NEOPLASTIC STEM CELLS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903477100     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn5014484     Document Type: Article

References (75)

1. Nagasawa, D. T.; Chow, F.; Yew, A.; Kim, W.; Cremer, N.; Yang, I. Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme Neurosurg. Clin. North Am. 2012, 23, 307-322
2. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E., 2nd; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M. et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res. 2007, 13, 1253-1259 (Pubitemid 46424067)
3. Hou, L. C.; Veeravagu, A.; Hsu, A. R.; Tse, V. C. Recurrent Glioblastoma Multiforme: a Review of Natural History and Management Options Neurosurg. Focus 2006, 20, E5
4. Johannessen, T. C.; Bjerkvig, R.; Tysnes, B. B. DNA Repair and Cancer Stem-Like Cells-Potential Partners in Glioma Drug Resistance? Cancer Treat. Rev. 2008, 34, 558-567
5. Chamberlain, M. C. Temozolomide: Therapeutic Limitations in the Treatment of Adult High-Grade Gliomas Expert Rev. Neurother. 2010, 10, 1537-1544
6. Ma, J.; Murphy, M.; O'Dwyer, P. J.; Berman, E.; Reed, K.; Gallo, J. M. Biochemical Changes Associated with a Multidrug-Resistant Phenotype of a Human Glioma Cell Line with Temozolomide-Acquired Resistance Biochem. Pharmacol. 2002, 63, 1219-1228 (Pubitemid 34311991)
7. Fruehauf, J. P.; Brem, H.; Brem, S.; Sloan, A.; Barger, G.; Huang, W.; Parker, R. In Vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas Clin. Cancer Res. 2006, 12, 4523-4532 (Pubitemid 44297801)
8. 6-Methylguanine-DNA Methyltransferase (MGMT) via Interaction with Sp1 Transcription Factor Anticancer Res. 2009, 29, 3741-3750
9. 6-Benzylguanine for Patients with Recurrent or Progressive Malignant Glioma J. Clin. Oncol. 2005, 23, 7178-7187
10. Liu, L.; Gerson, S. L. Targeted Modulation of MGMT: Clinical Implications Clin. Cancer Res. 2006, 12, 328-331 (Pubitemid 43166117)
11. Kanzawa, T.; Bedwell, J.; Kondo, Y.; Kondo, S.; Germano, I. M. Inhibition of DNA Repair for Sensitizing Resistant Glioma Cells to Temozolomide J. Neurosurg. 2003, 99, 1047-1052 (Pubitemid 44717401)
12. Ohka, F.; Natsume, A.; Wakabayashi, T. Current Trends in Targeted Therapies for Glioblastoma Multiforme Neurol. Res. Int. 2012, 2012, 878425
13. Nagpal, J.; Jamoona, A.; Gulati, N. D.; Mohan, A.; Braun, A.; Murali, R.; Jhanwar-Uniyal, M. Revisiting the Role of p53 in Primary and Secondary Glioblastomas Anticancer Res. 2006, 26, 4633-4639 (Pubitemid 46032092)
14. Zheng, H.; Ying, H.; Yan, H.; Kimmelman, A. C.; Hiller, D. J.; Chen, A. J.; Perry, S. R.; Tonon, G.; Chu, G. C.; Ding, Z. et al. p53 and Pten Control Neural and Glioma Stem/Progenitor Cell Renewal and Differentiation Nature 2008, 455, 1129-1133
15. Ohgaki, H.; Dessen, P.; Jourde, B.; Horstmann, S.; Nishikawa, T.; Di Patre, P. L.; Burkhard, C.; Schuler, D.; Probst-Hensch, N. M.; Maiorka, P. C. et al. Genetic Pathways to Glioblastoma: a Population-Based Study Cancer Res. 2004, 64, 6892-6899 (Pubitemid 39330996)
16. Srivenugopal, K. S.; Shou, J.; Mullapudi, S. R.; Lang, F. F., Jr.; Rao, J. S.; Ali-Osman, F. Enforced Expression of Wild-Type p53 Curtails the Transcription of the O(6)-Methylguanine-DNA Methyltransferase Gene in Human Tumor Cells and Enhances Their Sensitivity to Alkylating Agents Clin. Cancer Res. 2001, 7, 1398-1409 (Pubitemid 32708697)
17. Cerrato, J. A.; Yung, W. K.; Liu, T. J. Introduction of Mutant p53 into a Wild-Type p53-Expressing Glioma Cell Line Confers Sensitivity to Ad-p53-Induced Apoptosis Neuro-Oncol. 2001, 3, 113-122 (Pubitemid 33691768)
18. Bobustuc, G. C.; Baker, C. H.; Limaye, A.; Jenkins, W. D.; Pearl, G.; Avgeropoulos, N. G.; Konduri, S. D. Levetiracetam Enhances p53-Mediated MGMT Inhibition and Sensitizes Glioblastoma Cells to Temozolomide Neuro-Oncol. 2010, 12, 917-927
19. Sato, A.; Sunayama, J.; Matsuda, K.; Seino, S.; Suzuki, K.; Watanabe, E.; Tachibana, K.; Tomiyama, A.; Kayama, T.; Kitanaka, C. MEK-ERK Signaling Dictates DNA-Repair Gene MGMT Expression and Temozolomide Resistance of Stem-Like Glioblastoma Cells via the MDM2-p53 Axis Stem Cells 2011, 29, 1942-1951
20. Daniels, T. R.; Bernabeu, E.; Rodríguez, J. A.; Patel, S.; Kozman, M.; Chiappetta, D. A.; Holler, E.; Ljubimova, J. Y.; Helguera, G.; Penichet, M. L. The Transferrin Receptor and the Targeted Delivery of Therapeutic Agents Against Cancer Biochim. Biophys. Acta 2012, 1820, 291-317
21. Xu, L.; Frederik, P.; Pirollo, K. F.; Tang, W. H.; Rait, A.; Xiang, L. M.; Huang, W.; Cruz, I.; Yin, Y.; Chang, E. H. Self-Assembly of a Virus-Mimicking Nanostructure System for Efficient Tumor-Targeted Gene Delivery Hum. Gene Ther. 2002, 13, 469-481 (Pubitemid 34251511)
22. Xu, L.; Pirollo, K. F.; Tang, W. H.; Rait, A.; Chang, E. H. Transferrin-Liposome-Mediated Systemic p53 Gene Therapy in Combination with Radiation Results in Regression of Human Head and Neck Cancer Xenografts Hum. Gene Ther. 1999, 10, 2941-2952
23. Xu, L.; Tang, W. H.; Huang, C. C.; Alexander, W.; Xiang, L. M.; Pirollo, K. F.; Rait, A.; Chang, E. H. Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv Mol. Med. 2001, 7, 723-734 (Pubitemid 33070986)
24. Xu, L.; Huang, C. C.; Huang, W.; Tang, W. H.; Rait, A.; Yin, Y. Z.; Cruz, I.; Xiang, L. M.; Pirollo, K. F.; Chang, E. H. Systemic Tumor-Targeted Gene Delivery by Anti-Transferrin Receptor scFv-Immunoliposomes Mol. Cancer Ther. 2002, 1, 337-346
25. Pirollo, K. F.; Rait, A.; Zhou, Q.; Zhang, X. Q.; Zhou, J.; Kim, C. S.; Benedict, W. F.; Chang, E. H. Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In Vitro and In Vivo Clin. Cancer Res. 2008, 14, 2190-2198 (Pubitemid 351551132)
26. Yu, W.; Pirollo, K. F.; Yu, B.; Rait, A.; Xiang, L.; Huang, W.; Zhou, Q.; Ertem, G.; Chang, E. H. Enhanced Transfection Efficiency of a Systemically Delivered Tumor-Targeting Immunolipoplex by Inclusion of a pH-Sensitive Histidylated Oligolysine Peptide Nucleic Acids Res. 2004, 32, e48
27. Pirollo, K. F.; Zon, G.; Rait, A.; Zhou, Q.; Yu, W.; Hogrefe, R.; Chang, E. H. Tumor-Targeting Nanoimmunoliposome Complex for Short Interfering RNA Delivery Hum. Gene Ther. 2006, 17, 117-124 (Pubitemid 43100520)
28. Pirollo, K. F.; Rait, A.; Zhou, Q.; Hwang, S. H.; Dagata, J. A.; Zon, G.; Hogrefe, R. I.; Palchik, G.; Chang, E. H. Materializing the Potential of Small Interfering RNA via a Tumor-Targeting Nanodelivery System Cancer Res. 2007, 67, 2938-2943 (Pubitemid 46724828)
29. Hwang, S. H.; Rait, A.; Pirollo, K. F.; Zhou, Q.; Yenugonda, V. M.; Chinigo, G. M.; Brown, M. L.; Chang, E. H. Tumor-Targeting Nanodelivery Enhances the Anticancer Activity of a Novel Quinazolinone Analogue Mol. Cancer Ther. 2008, 7, 559-568 (Pubitemid 351482139)
30. Senzer, N.; Nemunaitis, J.; Nemunaitis, D.; Bedell, C.; Edelman, G.; Barve, M.; Nunan, R.; Pirollo, K. F.; Rait, A.; Chang, E. H.; Phase, I. Study of a Systemically Delivered p53 Nanoparticle in Advanced Solid Tumors Mol. Ther. 2013, 21, 1096-1103
31. Nathanson, D.; Mischel, P. S. Charting the Course Across the Blood-Brain Barrier J. Clin. Invest. 2011, 121, 31-33
32. Kim, S. S.; Rait, A.; Rubab, F.; Rao, A. K.; Kiritsy, M. C.; Pirollo, K. F.; Wang, S.; Weiner, L. M.; Chang, E. H. The Clinical Potential of Targeted Nanomedicine: Delivering to Cancer Stem-Like Cells Mol. Ther. 2014, 22, 278-291
33. Dagata, J. A.; Farkas, N.; Dennis, C. L.; Shull, R. D.; Hackley, V. A.; Yang, C.; Pirollo, K. F.; Chang, E. H. Physical Characterization Methods for Iron Oxide Contrast Agents Encapsulated within a Targeted Liposome-Based Delivery System Nanotechnology 2008, 19, 305101
34. Farkas, N.; Dagata, J. A.; Yang, C.; Rait, A.; Pirollo, K. F.; Chang, E. H. Combined Scanning Probe and Light Scattering Characterization of Multi-Stage Self-Assembly of Targeted Liposome-Based Delivery Systems Meas. Sci. Technol. 2011, 22, 024006
35. Bajgai, M. P.; Aryal, S.; Lee, D. R.; Park, S.-J.; Kim, H. Y. Physicochemical Characterization of Self-Assembled Poly(â̂̂- caprolactone) Grafted Dextran Nanoparticles Colloid Polym. Sci. 2008, 286, 517-524
36. Tabatt, K.; Kneuer, C.; Sameti, M.; Olbrich, C.; Müller, R. H.; Lehr, C. M.; Bakowsky, U. Transfection with Different Colloidal Systems: Comparison of Solid Lipid Nanoparticles and Liposomes J. Controlled Release 2004, 97, 321-332 (Pubitemid 38759489)
37. Nakano, K.; Tozuka, Y.; Yamamoto, H.; Kawashima, Y.; Takeuchi, H. A Novel Method for Measuring Rigidity of Submicron-Size Liposomes with Atomic Force Microscopy Int. J. Pharm. 2008, 355, 203-209
38. Gohy, J.-F.; Hofmeier, H.; Alexeev, A.; Schubert, U. S. Aqueous Micelles from Supramolecular Graft Copolymers Macromol. Chem. Phys. 2003, 204, 1524-1530
39. Thomson, N. H.; Collin, I.; Davies, M. C.; Palin, K.; Parkins, D.; Roberts, C. J.; Tendler, S. J. B.; Williams, P. M. Atomic Force Microscopy of Cationic Liposomes Langmuir 2000, 16, 4813-4818
40. Volcke, C.; Pirotton, S.; Grandfils, Ch.; Humbert, C.; Thiry, P. A.; Ydens, I.; Dubois, P.; Raes, M. Influence of DNA Condensation State on Transfection Efficiency in DNA/Polymer Complexes: An AFM and DLS Comparative Study J. Biotechnol. 2006, 125, 11-21 (Pubitemid 44066608)
41. Guo, S.; Huang, L. Nanoparticles Escaping RES and Endosome: Challenges for siRNA Delivery for Cancer Therapy J. Nanomater. 2011, 2011, 742895
42. Hegi, M. E.; Diserens, A. C.; Gorlia, T.; Hamou, M. F.; de Tribolet, N.; Weller, M.; Kros, J. M.; Hainfellner, J. A.; Mason, W.; Mariani, L. et al. MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma N. Engl. J. Med. 2005, 352, 997-1003 (Pubitemid 40349502)
43. Kitange, G. J.; Carlson, B. L.; Mladek, A. C.; Decker, P. A.; Schroeder, M. A.; Wu, W.; Grogan, P. T.; Giannini, C.; Ballman, K. V.; Buckner, J. C. et al. Evaluation of MGMT Promoter Methylation Status and Correlation with Temozolomide Response in Orthotopic Glioblastoma Xenograft Model J. Neurooncol. 2009, 92, 23-31
44. Martin, S.; Janouskova, H.; Dontenwill, M. Integrins and p53 Pathways in Glioblastoma Resistance to Temozolomide Front. Oncol. 2012, 2, 157
45. 6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts Int. J. Radiat. Oncol., Biol., Phys. 2009, 75, 212-219
46. Combs, S. E.; Rieken, S.; Wick, W.; Abdollahi, A.; von Deimling, A.; Debus, J.; Hartmann, C. Prognostic Significance of IDH-1 and MGMT in Patients with Glioblastoma: One Step Forward, and One Step Back? Radiat. Oncol. 2011, 6, 115
47. Xu, G. W.; Mymryk, J. S.; Cairncross, J. G. Pharmaceutical-Mediated Inactivation of p53 Sensitizes U87MG Glioma Cells to BCNU and Temozolomide Int. J. Cancer 2005, 116, 187-192 (Pubitemid 40967254)
48. Xu, G. W.; Mymryk, J. S.; Cairncross, J. G. Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin J. Neurooncol. 2005, 74, 141-149 (Pubitemid 41478909)
49. Hirose, Y.; Berger, M. S.; Pieper, R. O. p53 Effects both the Duration of G2/M Arrest and the Fate of Temozolomide-Treated Human Glioblastoma Cells Cancer Res. 2001, 61, 1957-1963 (Pubitemid 32692013)
50. Blough, M. D.; Beauchamp, D. C.; Westgate, M. R.; Kelly, J. J.; Cairncross, J. G. Effect of Aberrant p53 Function on Temozolomide Sensitivity of Glioma Cell Lines and Brain Tumor Initiating Cells from Glioblastoma J. Neurooncol. 2011, 102, 1-7
51. 6-Methylguanine DNA Methyltransferase and p53 Status Predict Temozolomide Sensitivity in Human Malignant Glioma Cells J. Neurochem. 2006, 96, 766-776
52. 6-Methylguanine Oncogene 2007, 26, 186-197 (Pubitemid 46095730)
53. Zhang, W. B.; Wang, Z.; Shu, F.; Jin, Y. H.; Liu, H. Y.; Wang, Q. J.; Yang, Y. Activation of AMP-Activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition J. Biol. Chem. 2010, 285, 40461-40471
54. Frosina, G. DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy Mol. Cancer Res. 2009, 7, 989-999
55. Dean, M.; Fojo, T.; Bates, S. Tumour Stem Cells and Drug Resistance Nat. Rev. Cancer 2005, 5, 275-284 (Pubitemid 40488633)
56. Visvader, J. E.; Lindeman, G. J. Cancer Stem Cells in Solid Tumours: Accumulating Evidence and Unresolved Questions Nat. Rev. Cancer 2008, 8, 755-768
57. Eramo, A.; Ricci-Vitiani, L.; Zeuner, A.; Pallini, R.; Lotti, F.; Sette, G.; Pilozzi, E.; Larocca, L. M.; Peschle, C.; De Maria, R. Chemotherapy Resistance of Glioblastoma Stem Cells Cell Death Differ. 2006, 13, 1238-1241 (Pubitemid 43905604)
58. Beier, D.; Schulz, J. B.; Beier, C. P. Chemoresistance of Glioblastoma Cancer Stem Cells-Much More Complex Than Expected Mol. Cancer 2011, 10, 128
59. Miaczynska, M.; Bar-Sagi, D. Signaling Endosomes: Seeing is Believing Curr. Opin. Cell Biol. 2010, 22, 535-540
60. Zbinden, M.; Duquet, A.; Lorente-Trigos, A.; Ngwabyt, S. N.; Borges, I.; Ruiz, i; Altaba, A. NANOG Regulates Glioma Stem Cells and is Essential In Vivo Acting in a Cross-Functional Network with GLI1 and p53 EMBO J. 2010, 29, 2659-2674
61. Zheng, H.; Ying, H.; Yan, H.; Kimmelman, A. C.; Hiller, D. J.; Chen, A. J.; Perry, S. R.; Tonon, G.; Chu, G. C.; Ding, Z. et al. Pten and p53 Converge on c-Myc to Control Differentiation, Self-Renewal, and Transformation of Normal and Neoplastic Stem Cells in Glioblastoma Cold Spring Harbor Symp. Quant. Biol. 2008, 73, 427-437
62. Jiang, G.; Wei, Z. P.; Pei, D. S.; Xin, Y.; Liu, Y. Q.; Zheng, J. N. A Novel Approach to Overcome Temozolomide Resistance in Glioma and Melanoma: Inactivation of MGMT by Gene Therapy Biochem. Biophys. Res. Commun. 2011, 406, 311-314
63. Tentori, L.; Graziani, G. Recent Approaches to Improve the Antitumor Efficacy of Temozolomide Curr. Med. Chem. 2009, 16, 245-257
64. Shah, G. D.; Socci, N. D.; Gold, J. S.; Wolchok, J. D.; Carvajal, R. D.; Panageas, K. S.; Viale, A.; Brady, M. S.; Coit, D. G.; Chapman, P. B. Phase II Trial of Neoadjuvant Temozolomide in Resectable Melanoma Patients Ann. Oncol. 2010, 21, 1718-1722
65. Patel, P. M.; Suciu, S.; Mortier, L.; Kruit, W. H.; Robert, C.; Schadendorf, D.; Trefzer, U.; Punt, C. J.; Dummer, R.; Davidson, N. et al. Extended Schedule, Escalated Dose Temozolomide Versus Dacarbazine in Stage IV Melanoma: Final Results of a Randomised Phase III Study (EORTC 18032) Eur. J. Cancer 2011, 47, 1476-1483
66. Laber, D. A.; Khan, M. I.; Kloecker, G. H.; Schonard, C.; Taft, B. S.; Salvador, C. A Phase I Study of Thalidomide, Capecitabine and Temozolomide in Advanced Cancer Cancer Biol. Ther. 2007, 6, 840-845 (Pubitemid 351574971)
67. Chan, J. A.; Stuart, K.; Earle, C. C.; Clark, J. W.; Bhargava, P.; Miksad, R.; Blaszkowsky, L.; Enzinger, P. C.; Meyerhardt, J. A.; Zheng, H. et al. Prospective Study of Bevacizumab Plus Temozolomide in Patients with Advanced Neuroendocrine Tumors J. Clin. Oncol. 2012, 30, 2963-2968
68. Siena, S.; Crino, L.; Danova, M.; Del Prete, S.; Cascinu, S.; Salvagni, S.; Schiavetto, I.; Vitali, M.; Bajetta, E. Dose-Dense Temozolomide Regimen for the Treatment of Brain Metastases from Melanoma, Breast Cancer, or Lung Cancer Not Amenable to Surgery or Radiosurgery: A Multicenter Phase II Study Ann. Oncol. 2010, 21, 655-661
69. Marosi, C. Complications of Chemotherapy in Neuro-Oncology. In Handbook of Clinical Neurology; Grisold, W.; Soffietti, R., Eds.; Elsevier: New York, 2012; pp 873-885.
70. 6-Methylguanine-DNA Methyltransferase (MGMT) Cancer Biol. Ther. 2010, 9, 49-55
71. 6-Methylguanine-DNA Methyltransferase in the Resistance of Pancreatic Tumors to DNA Alkylating Agents Cancer Res. 1997, 57, 5360-5368 (Pubitemid 27516375)
72. 6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors Clin. Cancer Res. 2009, 15, 338-345
73. Badie, B.; Goh, C. S.; Klaver, J.; Herweijer, H.; Boothman, D. A. Combined Radiation and p53 Gene Therapy of Malignant Glioma Cells Cancer Gene Ther. 1999, 6, 155-162 (Pubitemid 129667769)
74. Bahr, O.; Wick, W.; Weller, M. Modulation of MDR/MRP by Wild-Type and Mutant p53 J. Clin. Invest. 2001, 107, 643-646 (Pubitemid 32205187)
75. Teicher, B. A.; Menon, K.; Alvarez, E.; Galbreath, E.; Shih, C.; Faul, M. Antiangiogenic and Antitumor Effects of a Protein Kinase Cbeta Inhibitor in Human T98G Glioblastoma Multiforme Xenografts Clin. Cancer Res. 2001, 7, 634-640